namilumab

Home
Ligands
namilumab

GtoPdb Ligand ID: 10370

Synonyms: AMG203 [5] | MT203

Comment: Namilumab (AMG203, MT203) is an IgG1κ anti-macrophage colony-stimulating factor (GM-CSF; CSF2) monoclonal antibody [2]. It is being developed by Micromet and Nycomed for the treatment of autoimmune and chronic inflammatory diseases.
Peptide sequences and structural information for this antibody are available from its IMGT/mAb-DB entry.

References
1. Huizinga TW, Batalov A, Stoilov R, Lloyd E, Wagner T, Saurigny D, Souberbielle B, Esfandiari E. (2017) Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis. Arthritis Res Ther, 19 (1): 53. [PMID:28274253]
2. Krinner EM, Raum T, Petsch S, Bruckmaier S, Schuster I, Petersen L, Cierpka R, Abebe D, Mølhøj M, Wolf A et al.. (2007) A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF. Mol Immunol, 44 (5): 916-25. [PMID:16697465]
3. Papp KA, Gooderham M, Jenkins R, Vender R, Szepietowski JC, Wagner T, Hunt B, Souberbielle B, NEPTUNE investigators. (2019) Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody. Br J Dermatol, 180 (6): 1352-1360. [PMID:30207587]
4. Plater-Zyberk C, Joosten LA, Helsen MM, Hepp J, Baeuerle PA, van den Berg WB. (2007) GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice. Ann Rheum Dis, 66 (4): 452-7. [PMID:17020908]
5. Taylor PC, Saurigny D, Vencovsky J, Takeuchi T, Nakamura T, Matsievskaia G, Hunt B, Wagner T, Souberbielle B, NEXUS Study Group. (2019) Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial. Arthritis Res Ther, 21 (1): 101. [PMID:30999929]

References

1. Huizinga TW, Batalov A, Stoilov R, Lloyd E, Wagner T, Saurigny D, Souberbielle B, Esfandiari E. (2017)
Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis.
Arthritis Res Ther, 19 (1): 53. [PMID:28274253]

2. Krinner EM, Raum T, Petsch S, Bruckmaier S, Schuster I, Petersen L, Cierpka R, Abebe D, Mølhøj M, Wolf A et al.. (2007)
A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF.
Mol Immunol, 44 (5): 916-25. [PMID:16697465]

3. Papp KA, Gooderham M, Jenkins R, Vender R, Szepietowski JC, Wagner T, Hunt B, Souberbielle B, NEPTUNE investigators. (2019)
Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody.
Br J Dermatol, 180 (6): 1352-1360. [PMID:30207587]

4. Plater-Zyberk C, Joosten LA, Helsen MM, Hepp J, Baeuerle PA, van den Berg WB. (2007)
GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice.
Ann Rheum Dis, 66 (4): 452-7. [PMID:17020908]

5. Taylor PC, Saurigny D, Vencovsky J, Takeuchi T, Nakamura T, Matsievskaia G, Hunt B, Wagner T, Souberbielle B, NEXUS Study Group. (2019)
Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
Arthritis Res Ther, 21 (1): 101. [PMID:30999929]